The global e-prescribing market was valued at USD 2.9 billion in 2022 and it is predicted to surpass around USD 31.23 billion by 2032 with a CAGR of 26.83% from 2023 to 2032.
Key Pointers
Report Scope of the E-Prescribing Market
Report Coverage | Details |
Market Size in 2022 | USD 2.9 billion |
Revenue Forecast by 2032 | USD 31.23 billion |
Growth rate from 2023 to 2032 | CAGR of 26.83% |
Base Year | 2022 |
Forecast Period | 2023 to 2032 |
Regions Covered | North America, Europe, Asia Pacific, Latin America, Middle East & Africa |
Companies Covered | Cerner Corporation (Oracle); Allscripts Healthcare LLC; Epic Systems Corporation; DrFirst; Athenahealth; NXGN Management LLC; McKesson Corporation; Surescripts; Change Healthcare; Practice Fusion, Inc.; Networking Technology, Inc. (RXNT) |
Increasing adoption of electronic prescribing for controlled substances (EPSC) coupled with favorable government policies is expected to boost the market growth. At the federal level, the SUPPORT for Patients and Communities Act (H.R. 6), which Congress passed in October 2018, requires the use of electronic prescriptions for all controlled substances under Medicare Part D by January 1, 2021. Furthermore, rising awareness regarding patient safety is also anticipated to fuel market growth. During the COVID-19 pandemic, healthcare facilities were compelled to change their methods of providing their services to help curb the spread of infection among the general public and healthcare professionals. The demand for e-prescribing solutions increased, as it showed potential for improving access to prescription medicines as well as being convenient for patients. Market players also witnessed tremendous growth during the pandemic. For instance, Surescripts’ total number of e-Prescriptions exceeded 1 million prescribers in 2020.
New expansion activities, product approvals, product launches, partnerships, and acquisitions have positively impacted the e-prescribing market in recent years. For instance, in August 2021, Meddo, an India-based health startup, acquired Doxper, an e-prescription platform, which was founded in 2015 and deals in health record management and patient engagement solutions. Moreover, the market experienced a significant increase in the demand for e-prescription apps due to the growing digitalization, which in turn is fueling the market growth.
Electronic prescribing of controlled substances is now allowed in almost every state in the U.S. and Europe. The American Academy of Family Physicians (AAFP) has advocated for increased ease of EPCS implementation, and this process is improving. According to the World Health Organization, as of August 2021, around 70% of all drug use deaths are related to opioids and 30% are due to overdose. The opioid crisis in countries such as the U.S. is a major point of concern, which is expected to drive the demand for technologies such as e-prescribing. EPCS provides a secure, transparent system that makes it easier to prescribe controlled substances to patients who legitimately need them while making it more difficult to commit fraud or abuse.
Regional Insights
The e-prescribing market is dominant in North America, which accounted for about 44.02% share of global revenue in 2022. The major factor contributing to the growth of this region is the high number of government initiatives and incentives in the region. Europe is the second-largest market for e-prescription software, owing to the strict regulatory policies in European countries to prevent medical errors. Furthermore, initiatives by the EU are further anticipated to lead to regional growth.
While many countries do not accept e-prescriptions from other countries, the EU issued a circular in 2019 allowing the use of an e-prescription issued by a practitioner in a different country while visiting a pharmacy in another EU country. Asia Pacific region is anticipated to demonstrate the fastest growth of around 30.1% during the forecast period. This growth can be attributed to an increase in the penetration of technology and rising disposable income in the region.
E-Prescribing Market Segmentations:
By Product
By Delivery Mode
By End-use
By Usage Methods
By Substances
By Specialties
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Specialties Procurement Analysis
4.3.2. Sales and Distribution Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on E-Prescribing Market
5.1. COVID-19 Landscape: E-Prescribing Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global E-Prescribing Market, By Product
8.1. E-Prescribing Market, by Product, 2023-2032
8.1.1. Solutions
8.1.1.1. Market Revenue and Forecast (2020-2032)
8.1.2. Services
8.1.2.1. Market Revenue and Forecast (2020-2032)
Chapter 9. Global E-Prescribing Market, By Delivery Mode
9.1. E-Prescribing Market, by Delivery Mode, 2023-2032
9.1.1. Web/Cloud-Based
9.1.1.1. Market Revenue and Forecast (2020-2032)
9.1.2. On-premise
9.1.2.1. Market Revenue and Forecast (2020-2032)
Chapter 10. Global E-Prescribing Market, By End-use
10.1. E-Prescribing Market, by End-use, 2023-2032
10.1.1. Hospital
10.1.1.1. Market Revenue and Forecast (2020-2032)
10.1.2. Office-based Physicians
10.1.2.1. Market Revenue and Forecast (2020-2032)
10.1.3. Pharmacy
10.1.3.1. Market Revenue and Forecast (2020-2032)
Chapter 11. Global E-Prescribing Market, By Usage Methods
11.1. E-Prescribing Market, by Usage Methods, 2023-2032
11.1.1. Handheld
11.1.1.1. Market Revenue and Forecast (2020-2032)
11.1.2. Computer Based Devices
11.1.2.1. Market Revenue and Forecast (2020-2032)
Chapter 12. Global E-Prescribing Market, By Substances
12.1. E-Prescribing Market, by Substances, 2023-2032
12.1.1. Controlled Substances
12.1.1.1. Market Revenue and Forecast (2020-2032)
12.1.2. Non-controlled Substances
12.1.2.1. Market Revenue and Forecast (2020-2032)
Chapter 13. Global E-Prescribing Market, By Specialties
13.1. E-Prescribing Market, by Specialties, 2023-2032
13.1.1. Oncology
13.1.1.1. Market Revenue and Forecast (2020-2032)
13.1.2. Sports Medicine
13.1.2.1. Market Revenue and Forecast (2020-2032)
13.1.3. Neurology
13.1.3.1. Market Revenue and Forecast (2020-2032)
13.1.4. Cardiology
13.1.4.1. Market Revenue and Forecast (2020-2032)
13.1.5. Others
13.1.5.1. Market Revenue and Forecast (2020-2032)
Chapter 14. Global E-Prescribing Market, Regional Estimates and Trend Forecast
14.1. North America
14.1.1. Market Revenue and Forecast, by Product (2020-2032)
14.1.2. Market Revenue and Forecast, by Delivery Mode (2020-2032)
14.1.3. Market Revenue and Forecast, by End-use (2020-2032)
14.1.4. Market Revenue and Forecast, by Usage Methods (2020-2032)
14.1.5. Market Revenue and Forecast, by Substances (2020-2032)
14.1.6. Market Revenue and Forecast, by Specialties (2020-2032)
14.1.7. U.S.
14.1.7.1. Market Revenue and Forecast, by Product (2020-2032)
14.1.7.2. Market Revenue and Forecast, by Delivery Mode (2020-2032)
14.1.7.3. Market Revenue and Forecast, by End-use (2020-2032)
14.1.7.4. Market Revenue and Forecast, by Usage Methods (2020-2032)
14.1.8. Market Revenue and Forecast, by Substances (2020-2032)
14.1.8.1. Market Revenue and Forecast, by Specialties (2020-2032)
14.1.9. Rest of North America
14.1.9.1. Market Revenue and Forecast, by Product (2020-2032)
14.1.9.2. Market Revenue and Forecast, by Delivery Mode (2020-2032)
14.1.9.3. Market Revenue and Forecast, by End-use (2020-2032)
14.1.9.4. Market Revenue and Forecast, by Usage Methods (2020-2032)
14.1.10. Market Revenue and Forecast, by Substances (2020-2032)
14.1.11. Market Revenue and Forecast, by Specialties (2020-2032)
14.1.11.1.
14.2. Europe
14.2.1. Market Revenue and Forecast, by Product (2020-2032)
14.2.2. Market Revenue and Forecast, by Delivery Mode (2020-2032)
14.2.3. Market Revenue and Forecast, by End-use (2020-2032)
14.2.4. Market Revenue and Forecast, by Usage Methods (2020-2032)
14.2.5. Market Revenue and Forecast, by Substances (2020-2032)
14.2.6. Market Revenue and Forecast, by Specialties (2020-2032)
14.2.7.
14.2.8. UK
14.2.8.1. Market Revenue and Forecast, by Product (2020-2032)
14.2.8.2. Market Revenue and Forecast, by Delivery Mode (2020-2032)
14.2.8.3. Market Revenue and Forecast, by End-use (2020-2032)
14.2.9. Market Revenue and Forecast, by Usage Methods (2020-2032)
14.2.10. Market Revenue and Forecast, by Substances (2020-2032)
14.2.10.1. Market Revenue and Forecast, by Specialties (2020-2032)
14.2.11. Germany
14.2.11.1. Market Revenue and Forecast, by Product (2020-2032)
14.2.11.2. Market Revenue and Forecast, by Delivery Mode (2020-2032)
14.2.11.3. Market Revenue and Forecast, by End-use (2020-2032)
14.2.12. Market Revenue and Forecast, by Usage Methods (2020-2032)
14.2.13. Market Revenue and Forecast, by Substances (2020-2032)
14.2.14. Market Revenue and Forecast, by Specialties (2020-2032)
14.2.14.1.
14.2.15. France
14.2.15.1. Market Revenue and Forecast, by Product (2020-2032)
14.2.15.2. Market Revenue and Forecast, by Delivery Mode (2020-2032)
14.2.15.3. Market Revenue and Forecast, by End-use (2020-2032)
14.2.15.4. Market Revenue and Forecast, by Usage Methods (2020-2032)
14.2.16. Market Revenue and Forecast, by Substances (2020-2032)
14.2.16.1. Market Revenue and Forecast, by Specialties (2020-2032)
14.2.17. Rest of Europe
14.2.17.1. Market Revenue and Forecast, by Product (2020-2032)
14.2.17.2. Market Revenue and Forecast, by Delivery Mode (2020-2032)
14.2.17.3. Market Revenue and Forecast, by End-use (2020-2032)
14.2.17.4. Market Revenue and Forecast, by Usage Methods (2020-2032)
14.2.18. Market Revenue and Forecast, by Substances (2020-2032)
14.2.18.1. Market Revenue and Forecast, by Specialties (2020-2032)
14.3. APAC
14.3.1. Market Revenue and Forecast, by Product (2020-2032)
14.3.2. Market Revenue and Forecast, by Delivery Mode (2020-2032)
14.3.3. Market Revenue and Forecast, by End-use (2020-2032)
14.3.4. Market Revenue and Forecast, by Usage Methods (2020-2032)
14.3.5. Market Revenue and Forecast, by Substances (2020-2032)
14.3.6. Market Revenue and Forecast, by Specialties (2020-2032)
14.3.7. India
14.3.7.1. Market Revenue and Forecast, by Product (2020-2032)
14.3.7.2. Market Revenue and Forecast, by Delivery Mode (2020-2032)
14.3.7.3. Market Revenue and Forecast, by End-use (2020-2032)
14.3.7.4. Market Revenue and Forecast, by Usage Methods (2020-2032)
14.3.8. Market Revenue and Forecast, by Substances (2020-2032)
14.3.9. Market Revenue and Forecast, by Specialties (2020-2032)
14.3.10. China
14.3.10.1. Market Revenue and Forecast, by Product (2020-2032)
14.3.10.2. Market Revenue and Forecast, by Delivery Mode (2020-2032)
14.3.10.3. Market Revenue and Forecast, by End-use (2020-2032)
14.3.10.4. Market Revenue and Forecast, by Usage Methods (2020-2032)
14.3.11. Market Revenue and Forecast, by Substances (2020-2032)
14.3.11.1. Market Revenue and Forecast, by Specialties (2020-2032)
14.3.12. Japan
14.3.12.1. Market Revenue and Forecast, by Product (2020-2032)
14.3.12.2. Market Revenue and Forecast, by Delivery Mode (2020-2032)
14.3.12.3. Market Revenue and Forecast, by End-use (2020-2032)
14.3.12.4. Market Revenue and Forecast, by Usage Methods (2020-2032)
14.3.12.5. Market Revenue and Forecast, by Substances (2020-2032)
14.3.12.6. Market Revenue and Forecast, by Specialties (2020-2032)
14.3.13. Rest of APAC
14.3.13.1. Market Revenue and Forecast, by Product (2020-2032)
14.3.13.2. Market Revenue and Forecast, by Delivery Mode (2020-2032)
14.3.13.3. Market Revenue and Forecast, by End-use (2020-2032)
14.3.13.4. Market Revenue and Forecast, by Usage Methods (2020-2032)
14.3.13.5. Market Revenue and Forecast, by Substances (2020-2032)
14.3.13.6. Market Revenue and Forecast, by Specialties (2020-2032)
14.4. MEA
14.4.1. Market Revenue and Forecast, by Product (2020-2032)
14.4.2. Market Revenue and Forecast, by Delivery Mode (2020-2032)
14.4.3. Market Revenue and Forecast, by End-use (2020-2032)
14.4.4. Market Revenue and Forecast, by Usage Methods (2020-2032)
14.4.5. Market Revenue and Forecast, by Substances (2020-2032)
14.4.6. Market Revenue and Forecast, by Specialties (2020-2032)
14.4.7. GCC
14.4.7.1. Market Revenue and Forecast, by Product (2020-2032)
14.4.7.2. Market Revenue and Forecast, by Delivery Mode (2020-2032)
14.4.7.3. Market Revenue and Forecast, by End-use (2020-2032)
14.4.7.4. Market Revenue and Forecast, by Usage Methods (2020-2032)
14.4.8. Market Revenue and Forecast, by Substances (2020-2032)
14.4.9. Market Revenue and Forecast, by Specialties (2020-2032)
14.4.10. North Africa
14.4.10.1. Market Revenue and Forecast, by Product (2020-2032)
14.4.10.2. Market Revenue and Forecast, by Delivery Mode (2020-2032)
14.4.10.3. Market Revenue and Forecast, by End-use (2020-2032)
14.4.10.4. Market Revenue and Forecast, by Usage Methods (2020-2032)
14.4.11. Market Revenue and Forecast, by Substances (2020-2032)
14.4.12. Market Revenue and Forecast, by Specialties (2020-2032)
14.4.13. South Africa
14.4.13.1. Market Revenue and Forecast, by Product (2020-2032)
14.4.13.2. Market Revenue and Forecast, by Delivery Mode (2020-2032)
14.4.13.3. Market Revenue and Forecast, by End-use (2020-2032)
14.4.13.4. Market Revenue and Forecast, by Usage Methods (2020-2032)
14.4.13.5. Market Revenue and Forecast, by Substances (2020-2032)
14.4.13.6. Market Revenue and Forecast, by Specialties (2020-2032)
14.4.14. Rest of MEA
14.4.14.1. Market Revenue and Forecast, by Product (2020-2032)
14.4.14.2. Market Revenue and Forecast, by Delivery Mode (2020-2032)
14.4.14.3. Market Revenue and Forecast, by End-use (2020-2032)
14.4.14.4. Market Revenue and Forecast, by Usage Methods (2020-2032)
14.4.14.5. Market Revenue and Forecast, by Substances (2020-2032)
14.4.14.6. Market Revenue and Forecast, by Specialties (2020-2032)
14.5. Latin America
14.5.1. Market Revenue and Forecast, by Product (2020-2032)
14.5.2. Market Revenue and Forecast, by Delivery Mode (2020-2032)
14.5.3. Market Revenue and Forecast, by End-use (2020-2032)
14.5.4. Market Revenue and Forecast, by Usage Methods (2020-2032)
14.5.5. Market Revenue and Forecast, by Substances (2020-2032)
14.5.6. Market Revenue and Forecast, by Specialties (2020-2032)
14.5.7. Brazil
14.5.7.1. Market Revenue and Forecast, by Product (2020-2032)
14.5.7.2. Market Revenue and Forecast, by Delivery Mode (2020-2032)
14.5.7.3. Market Revenue and Forecast, by End-use (2020-2032)
14.5.7.4. Market Revenue and Forecast, by Usage Methods (2020-2032)
14.5.8. Market Revenue and Forecast, by Substances (2020-2032)
14.5.8.1. Market Revenue and Forecast, by Specialties (2020-2032)
14.5.9. Rest of LATAM
14.5.9.1. Market Revenue and Forecast, by Product (2020-2032)
14.5.9.2. Market Revenue and Forecast, by Delivery Mode (2020-2032)
14.5.9.3. Market Revenue and Forecast, by End-use (2020-2032)
14.5.9.4. Market Revenue and Forecast, by Usage Methods (2020-2032)
14.5.9.5. Market Revenue and Forecast, by Substances (2020-2032)
14.5.9.6. Market Revenue and Forecast, by Specialties (2020-2032)
Chapter 15. Company Profiles
15.1. Cerner Corporation (Oracle)
15.1.1. Company Overview
15.1.2. Product Offerings
15.1.3. Financial Performance
15.1.4. Recent Initiatives
15.2. Allscripts Healthcare LLC
15.2.1. Company Overview
15.2.2. Product Offerings
15.2.3. Financial Performance
15.2.4. Recent Initiatives
15.3. Epic Systems Corporation
15.3.1. Company Overview
15.3.2. Product Offerings
15.3.3. Financial Performance
15.3.4. Recent Initiatives
15.4. DrFirst
15.4.1. Company Overview
15.4.2. Product Offerings
15.4.3. Financial Performance
15.4.4. Recent Initiatives
15.5. Athenahealth
15.5.1. Company Overview
15.5.2. Product Offerings
15.5.3. Financial Performance
15.5.4. Recent Initiatives
15.6. NXGN Management LLC
15.6.1. Company Overview
15.6.2. Product Offerings
15.6.3. Financial Performance
15.6.4. Recent Initiatives
15.7. McKesson Corporation
15.7.1. Company Overview
15.7.2. Product Offerings
15.7.3. Financial Performance
15.7.4. Recent Initiatives
15.8. Surescripts
15.8.1. Company Overview
15.8.2. Product Offerings
15.8.3. Financial Performance
15.8.4. Recent Initiatives
15.9. Change Healthcare
15.9.1. Company Overview
15.9.2. Product Offerings
15.9.3. Financial Performance
15.9.4. Recent Initiatives
15.10. Practice Fusion, Inc.
15.10.1. Company Overview
15.10.2. Product Offerings
15.10.3. Financial Performance
15.10.4. Recent Initiatives
Chapter 16. Research Methodology
16.1. Primary Research
16.2. Secondary Research
16.3. Assumptions
Chapter 17. Appendix
17.1. About Us
17.2. Glossary of Terms